Seeking Alpha
View as an RSS Feed

Joe Springer  

View Joe Springer's Articles BY TICKER:
  • Michaels Companies Should Have Staying Power
    Fri, Feb. 13 MIK 1 Comment

    Summary

    • Michaels' in-store experience and the "hands-on" nature of arts and crafts should help protect Michaels from Amazon.
    • About half of Michaels' sales are of its own proprietary products, which are not available elsewhere and help increase foot traffic.
    • Michaels is the largest player in an industry that is very unlikely to be replaced by new technology.
  • Martin Marietta Materials: Hoya Saxa!
    Wed, Feb. 11 MLM 3 Comments

    Summary

    • Regulatory and permitting barriers to entry work extremely well for already established quarries, like the over 300 owned by Martin Marietta.
    • It does not make sense to transport rock and sand aggregates long distances, and the local players like Martin Marietta have pricing power.
    • If the US stays healthy, Martin Marietta should be able compound for years and decades.
  • 5 Reasons To Take A Look At Telkonet
    Mon, Feb. 2 TKOI 17 Comments

    Summary

    • Telkonet is a turnaround story, and though its turnaround seems to be in full motion, it has stayed under the radar.
    • Telkonet is very well positioned to capitalize on intelligent automation markets that should have significant growth for a long time.
    • Telkonet has an excellent business model and numerous catalysts that may help it realize asymmetric upside.
  • Tonix Is A Buy On Endpoint Circumstances
       • Sep. 30, 2014 TNXP 181 Comments

    Summary

    • BESTFIT missed its primary endpoint of mean change in pain.
    • BESTFIT did deliver benefits across the board though, including statistical significance in pain by three other measures, including the one used in the most recent approval in FM.
    • BESTFIT also demonstrated excellent safety and side effect data.
  • Unique Tonix Could Go Higher On BESTFIT Data
       • Sep. 24, 2014 TNXP 107 Comments

    Summary

    • Tonix is a unique company pursuing some of the largest challenges in medicine.
    • Tonix is on the verge of receiving pivotal top line data in its BESTFIT trial.
    • With good results, Tonix should soar.
  • Tonix Could Match Pfizer's Biggest Drug's Best Market
    Aug. 22, 2014 TNXP 89 Comments

    Summary

    • Pfizer's Best Selling Drug Lyrica is Growing Rapidly in the US Fibromyalgia Market.
    • Lyrica is Set to Eclipse $1 Billion in Annual Sales in the Market.
    • With Good Data and at 1/1,000 the Size, Tonix Pharmaceuticals Could Have the Sales Equivalent.
  • Tonix May Not Need Final Trial
    Aug. 8, 2014 TNXP 106 Comments

    Summary

    • After its first phase 3 trial Map Pharmaceuticals traded at 1 X sales without partners or analyst coverage.
    • Map then traded at 2 X sales after the FDA decided no final phase 3 trial was necessary.
    • If BESTFIT data is good, TNX-102 SL in FM has an excellent chance to do the same.
  • 10 Things To Know About Tonix Pharmaceuticals
    Aug. 4, 2014 TNXP 20 Comments

    Summary

    • BESTFIT Data Should Be Released Early Q4.
    • Data Should Be a Pivotal Event for Tonix.
    • Tonix Also Has Quite a Pipeline and Staff.
  • 10 Great Investments At Good Prices
    Jul. 29, 2014 BAH, CLD, DE 19 Comments

    Summary

    • The stock market has had a long bull run.
    • There are still great investments to be had at good prices.
    • We offer 10 suggestions.
  • Beat Most Fund Managers In One Step
    Jul. 9, 2014 VO 5 Comments

    Summary

    • Large-cap index funds are extremely popular.
    • Mid-cap index funds swap holdings with large cap funds.
    • As long as large-cap index funds enjoy their popularity, mid-cap index funds will enjoy an advantage.
  • The Best Passive Retirement Strategy In The World
    Jun. 26, 2014 VO 231 Comments

    Summary

    • Inflation may doom bond-holding retirees.
    • The equity markets provide the return and inflation protection retirees need.
    • A time buffer can allow retirees to move more money into equities.
  • Tonix Approaching 100 Days Until BESTFIT Results
    Jun. 19, 2014 TNXP 238 Comments

    Summary

    • BESTFIT trial results are about 100 days away.
    • TNX-102 SL is poised to be the first line therapy in fibromyalgia.
    • We expect favorable results from BESTFIT, and think the stock will approach $1 billion in market cap.
  • 4 Reasons Adamis Pharmaceuticals Could Be A Multi-Bagger
       • May. 15, 2014 ADMP 172 Comments

    Summary

    • Epinephrine Pre-Filled Syringe is Poised for Market Share - Revenues with high gross margins should start in 2015.
    • Taper DPI Should Generate a Lot of Revenue - Truly novel delivery device could generate more than $1 billion annually.
    • APC-1000 is One Trial From the Market - And looking to take share from the fastest growing drug in its class.
  • 5 Reasons Tonix Could Still Be A Multi-Bagger
       • Apr. 8, 2014 TNXP 24 Comments

    Summary

    • BESTFIT is on Schedule - All is well with TNX-102 SL in its pivotal fibromyalgia study.
    • Proof of Concept Study in PTSD is on Schedule - Could lead to Department of Defense grants and further development of newly acquired IP.
    • TNX-201 is on Schedule - Treatment for most common headache type should apply for approval in 2018.
    • Tonix’ IP is Very Strong and its Strategy Remains Intact - Tonix' lead products should have market exclusivity into the 2030s.
    • Value - We think data results in the fourth quarter will realize a $61.53 price per share.
  • 6 Doubles In A Row And 2014's Top Pick
    Dec. 13, 2013 FTEK, HYGS, IMUC 117 Comments
  • 4 Reasons Tonix Could Be A Multi-Bagger
       • Dec. 3, 2013 TNXP 274 Comments
  • How Do You Fake 7 Of 16 Five-Year Glioblastoma Survivors?
    Nov. 13, 2013 IMUC 433 Comments
  • 6 Reasons ImmunoCellular Therapeutics Is One Of The Best Risk Vs. Rewards In The Market
       • Aug. 7, 2013 IMUC 427 Comments
  • 5 Reasons Hydrogenics Could Triple
       • May. 24, 2013 HYGS 176 Comments
  • With Plenty Of Cash, Hydrogenics Is A Buy
    Apr. 30, 2013 HYGS 82 Comments
  • MannKind's Afrezza Likely To Easily Gain Approval
    Apr. 15, 2013 MNKD 169 Comments
  • 5 Reasons MannKind Could Be The Best Performing Stock Of 2013
       • Mar. 8, 2013 MNKD 219 Comments
  • 3 Reasons TravelCenters Of America Could Triple
    Editors' Pick • Jan. 14, 2013 TA 114 Comments
  • Apple: Get Ready For January 18
    Editors' Pick • Jan. 13, 2013 AAPL 248 Comments
  • 6 Reasons Fuel Tech Could Triple
       • Dec. 17, 2012 FTEK 22 Comments
  • $100,000 Bold Trader's Portfolio: 3 Bold Trades
    Nov. 16, 2012 AEM, BAC, QQQ 9 Comments
  • Buy Apple On January 18
    Nov. 13, 2012 AAPL 158 Comments
  • $33,000 Portfolio: Mostly Cash Ahead Of Elections And Snow-Hurricanes
    Oct. 30, 2012 ACI, AGXXF, AMZN 26 Comments
  • Put Writing: Make Money With Coal 'Insurance' (Video)
    Oct. 7, 2012 ACI 6 Comments
  • 4 Options Trades For Arch Coal (Video)
    Oct. 6, 2012 ACI 3 Comments
  • Romney Scares Coal Shorts (Video)
    Oct. 5, 2012 ACI 14 Comments
  • 5 Bio-Pharma Stocks To Buy Right Here
    Aug. 24, 2012 ARNA, ATRS, MNKD 28 Comments